What You'll Want to Know About Corbus Pharmaceuticals' Q2 Results
Corbus Pharmaceuticals (NASDAQ: CRBP) has had some good news so far in 2019. Its shares soared in April after Jefferies initiated coverage on the stock with a buy rating and a one-year price target that was more than double its share price at the time. Since then, though, Corbus' share price has drifted downward.
Investors received a little more good news when Corbus announced its second-quarter results before the market opened on Thursday. Here's what you need to know from the biotech's Q2 update.
Image source: Getty Images.
Quelle Fool.com
